DelMar Pharmaceuticals, Inc. (DMPI) financial statements (2021 and earlier)

Company profile

Business Address 12707 HIGH BLUFF DR., SUITE 200
SAN DIEGO, CA 92130
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17246762
Cash and cash equivalents17246762
Receivables      0
Prepaid expense1001100
Deferred costs 0    1
Other undisclosed current assets000000 
Total current assets:18347863
Noncurrent Assets
Property, plant and equipment0      
Intangible assets, net (including goodwill) 00000 
Intangible assets, net (excluding goodwill) 00000 
Deferred costs 0     
Other undisclosed noncurrent assets3      
Total noncurrent assets:300000 
Other undisclosed assets      0
TOTAL ASSETS:20347863
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2221111
Other undisclosed accounts payable and accrued liabilities2221111
Debt0      
Derivative instruments and hedges, liabilities    0  
Due to related parties0100000
Other undisclosed current liabilities(0)      
Total current liabilities:3322111
Noncurrent Liabilities
Liabilities, other than long-term debt   0011
Derivative instruments and hedges, liabilities   0011
Other undisclosed noncurrent liabilities0    00
Total noncurrent liabilities:0  0011
Total liabilities:3322112
Stockholders' equity
Stockholders' equity attributable to parent, including:18025751
Preferred stock      0
Common stock0000000
Additional paid in capital9457514337292
Accumulated other comprehensive income0000000
Accumulated deficit(98)(70)(61)(52)(41)(32)(23)
Warrants and rights outstanding 978526
Other undisclosed stockholders' equity attributable to parent225566716
Total stockholders' equity:18025751
TOTAL LIABILITIES AND EQUITY:20347863

Income statement (P&L) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Operating expenses(31)(9)811(8)(6)5
Other operating income, net00     
Operating income (loss):(31)(9)811(8)(6)5
Nonoperating income (expense)(0)0(0)(0)(0)(3)0
Investment income, nonoperating  (0)(0)(0)(2)(0)
Foreign currency transaction gain (loss), before tax(0)(0)00 (0)0
Interest and debt expense(0)     0
Income (loss) before gain (loss) on sale of properties:(31)(9)811(9)(9)5
Other undisclosed net loss(0)(0)(16)(22)   
Net income (loss):(31)(9)(8)(11)(9)(9)5
Other undisclosed net income (loss) attributable to parent  162217 (10)
Net income (loss) attributable to parent:(31)(9)8118(9)(5)
Preferred stock dividends and other adjustments(0)(0)001  
Other undisclosed net loss available to common stockholders, basic(3)      
Net income (loss) available to common stockholders, diluted:(34)(9)8119(9)(5)

Comprehensive Income ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net income (loss):(31)(9)(8)(11)(9)(9)5
Comprehensive income (loss):(31)(9)(8)(11)(9)(9)5
Other undisclosed comprehensive loss, net of tax, attributable to parent      (0)
Comprehensive income (loss), net of tax, attributable to parent:(31)(9)(8)(11)(9)(9)5

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: